glycosidase-in-1

Glycosidase-IN-1 is a glycosidase inhibitor synthesized from D-mannose with hypoglycemic activity. It can be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors.

β-glycosidase-IN-1 is a piperidine derivative, and is an inhibitor of β-glycosidase. It has hypoglycemic activity.

α-Glycosidase-IN-1 (compound MZ7) is a potent inhibitor of α-GLY (α-glycosidase) with an IC50 of 44.72 nM and a Ki of 44.74 nM. It also inhibits human carbonic anhydrase isozymes I (hCA I) and II (hCA II) with IC50 values of 104.87 nM and 100.04 nM, respectively, and acetylcholine esterase (AChE) with an IC50 value of 654.87 nM. α-Glycosidase-IN-1 is applicable in the study of diabetes, Alzheimer's disease, ulcers, heart failure, epilepsy, and various other diseases.

Endoglycoceramidase I (EGCase I), a glycosidase frequently utilized in biochemical studies, catalyzes a transglycosylation reaction. This process involves transferring the sugar moiety of GSLs to the primary hydroxyl group of various 1-alkanols [1].

α-Galactosidase is an endogenous glycosidase that can break down oligosaccharides and glycolipids containing α-galactoside bonds and can be used in the study of Fabry disease.

PNGase F, a glycosidase, catalyzes the cleavage of internal glycoside bonds in oligosaccharides and removes nearly all N-linked oligosaccharides from glycoproteins [1] [2].

KY371, a click chemistry reagent containing an alkyne group, is a broad-range glycosidase inhibitor that can be used in conjunction with proteomic analysis of targeted proteins to study glycosidases [1].